Amgen

Open: 284.5 Close: 286.53 Change: 2.03

Are you still looking for information about Amgen Company Inc? An AI summarized it for you.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, estimate, Amgens, provide, regulatory, update, status, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen raises dividend to $2.25 a share for first quarter of 2024. Amgen is 135.32% away from the 52-week low. FDA approves Amgen biosimilar challenge to J&Js Stelara with interchangeable designation.

Today's News

Amgens stock rose 0.7% in premarket trading, while futures ES00 for the S&P 500 SPX edged up 0.1%. Amgen currently carries a Zacks Rank #3 (Hold) Amgen stock has received a consensus rating of buy. The 69 analysts offering price forecasts for Amgen have a median target of 264.90, with a high estimate of 326.00 and a low estimate of 182.00. Amgen is 135.32% away from the 52-week low. Amgen announces 2024 First Quarter Dividend Increase to $2.25 per share. Amgen to present at the Evercore ISI HealthCONx Conference. Amgen announces presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio. FDA approves Amgen biosimilar challenge to J&Js Stelara with interchangeable designation. Amgen raises dividend to $2.25 a share for the first quarter of 2024. Senator Elizabeth Warren expresses disappointment in FTC decision in antitrust decision. Amgen announced that the U.S. FDA Grants Priority Review to Amgens Tarlatamab Application for Advanced Small Cell Lung Cancer. Amgen Announces 2024 First Quarter Dividend Increase to $2.25 Per Share. Amgen provides regulatory update on status of lumakras® (sotorasib) Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen provides regulatory update on status of lumakras® (sotorasib) Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen provides regulatory update on status of lumakras® (sotorasib) Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen provides regulatory update on status of lumakras® (sotorasib) LUMAKRAS Dosing Confirmed at 960 mgDaily for Patients. Amgen is one of 30 companies that comprise the Dow Jones Industrial Average. Amgen is one of Americas Greatest Workplaces by Newsweek and one of the Worlds Best Companies by TIME. Be part of Amgens newest and most advanced drug substance manufacturing plant. Amgen is one of the worlds leading independent biotechnology companies. Japan and Asia Pacific (JAPAC) is the fastest growing region in Amgen. We are hiring an Associate Director, Process Development, Amgen Singapore Manufacturing. Amgen is rated Zacks Rank #3 (Hold) due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates. Amgen reported revenues of $6.9 billion in the last reported quarter, representing a year-over-year change of +3.8%. Amgens sales estimate of $8.13 billion for the current quarter is well respected having 1972 of coll Case cooperCLASSIFIEDAbove EXPatio compressorJuly MetWing

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, estimate, Amgens, provide, regulatory, update, status, and the most common words in the summary are: amgen, news, stock, lumakras, market, inc, development, . One of the sentences in the summary was: Amgen is 135.32% away from the 52-week low. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #stock #lumakras #market #inc #development.